Literature DB >> 7798650

Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium.

F Caron1, M Pestel, M D Kitzis, J F Lemeland, G Humbert, L Gutmann.   

Abstract

A synergistic bactericidal effect between penicillin, vancomycin, and gentamicin has been described against enterococci highly resistant to beta-lactams and glycopeptides. Since such a synergy was also observed in vitro between ceftriaxone, teicoplanin, and gentamicin against Enterococcus faecium 70/90, the efficacy of different combinations including penicillin or ceftriaxone, vancomycin or teicoplanin, and gentamicin was compared in vivo in experimental endocarditis. In vitro, all four triple combinations provided a bactericidal effect. In rabbits, after a 5-day treatment, the ceftriaxone-vancomycin-gentamicin combination was the most effective, both in reducing the total bacterial titers and in eradicating the subpopulation resistant to the synergy. Compared with the 5-day regimen, 10- and 20-day regimens of ceftriaxone-vancomycin-gentamicin, each followed by a 3-day antibiotic-free period, increased the number of sterilized animals but failed to avoid the emergence of resistant bacteria, which occurred in 10%-20% of animals.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7798650     DOI: 10.1093/infdis/171.1.106

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

Review 1.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

Review 3.  Treatment options for vancomycin-resistant enterococcal infections.

Authors:  Peter K Linden
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.

Authors:  R C Mercier; S R Penzak; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Comparative efficacies of liposomal amikacin (MiKasome) plus oxacillin versus conventional amikacin plus oxacillin in experimental endocarditis induced by Staphylococcus aureus: microbiological and echocardiographic analyses.

Authors:  Y Q Xiong; L I Kupferwasser; P M Zack; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  In Vitro Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant Enterococcus faecium and Carbapenem-Resistant Enterobacter cloacae Bacteremia in a Liver Transplant Patient.

Authors:  Eric Wenzler; Maressa Santarossa; Kevin A Meyer; Amanda T Harrington; Gail E Reid; Nina M Clark; Fritzie S Albarillo; Zackery P Bulman
Journal:  Open Forum Infect Dis       Date:  2020-01-04       Impact factor: 3.835

7.  Clinico-epidemiological profile and high-level aminoglycoside resistance in enterococcal septicemia from a tertiary care hospital in east Delhi.

Authors:  Sarika Jain; Ashwani Kumar; Bineeta Kashyap; Iqbal R Kaur
Journal:  Int J Appl Basic Med Res       Date:  2011-07

Review 8.  Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future.

Authors:  M M Huycke; D F Sahm; M S Gilmore
Journal:  Emerg Infect Dis       Date:  1998 Apr-Jun       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.